journal
MENU ▼
Read by QxMD icon Read
search

JACC. Heart Failure

journal
https://www.readbyqxmd.com/read/29655826/exploiting-the-natriuretic-peptide-pathway-to-preserve-glomerular-filtration-in-heart-failure
#1
EDITORIAL
Wilfried Mullens, Pieter Martens
No abstract text is available yet for this article.
April 11, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655830/medicare-expenditures-by-race-ethnicity-after-hospitalization-for-heart-failure-with-preserved-ejection-fraction
#2
Boback Ziaeian, Paul A Heidenreich, Haolin Xu, Adam D DeVore, Roland A Matsouaka, Adrian F Hernandez, Deepak L Bhatt, Clyde W Yancy, Gregg C Fonarow
OBJECTIVES: The purpose of this study was to analyze cumulative Medicare expenditures at index admission and after discharge by race or ethnicity. BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a growing proportion of heart failure (HF) admissions. Research on health care expenditures for patients with HFpEF is limited. METHODS: Records of patients discharged from the Get With The Guidelines-Heart Failure registry between 2006 and 2014 were linked to Medicare data...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655829/renal-effects-and-associated-outcomes-during-angiotensin-neprilysin-inhibition-in-heart-failure
#3
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg, Michael R Zile, Milton Packer, Akshay S Desai, Scott D Solomon, John J V McMurray
OBJECTIVES: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. BACKGROUND: Renal function is frequently impaired in patients with heart failure with reduced ejection fraction and may deteriorate further after blockade of the renin-angiotensin system. METHODS: In the PARADIGM-HF (Prospective Comparison of ARNI with ACE inhibition to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, 8,399 patients with heart failure with reduced ejection fraction were randomized to treatment with sacubitril/valsartan or enalapril...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655828/venoarterial-extracorporeal-membrane-oxygenation-in-cardiogenic-shock
#4
REVIEW
Mary E Keebler, Elias V Haddad, Chun W Choi, Stuart McGrane, Sandip Zalawadiya, Kelly H Schlendorf, D Marshall Brinkley, Matthew R Danter, Mark Wigger, Jonathan N Menachem, Ashish Shah, JoAnn Lindenfeld
Venoarterial extracorporeal membrane oxygenation has emerged as a viable treatment for patients in cardiogenic shock with biventricular failure and pulmonary dysfunction. Advances in pump and oxygenator technology, cannulation strategies, patient selection and management, and durable mechanical circulatory support have contributed to expanded utilization of this technology. However, challenges remain that require investigation to improve outcomes.
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655827/30-day-episode-payments-and-heart-failure-outcomes-among-medicare-beneficiaries
#5
Rishi K Wadhera, Karen E Joynt Maddox, Yun Wang, Changyu Shen, Robert W Yeh
OBJECTIVES: The purpose of this study was to examine the association of 30-day payments for an episode of heart failure (HF) care at the hospital level with patient outcomes. BACKGROUND: There is increased focus among policymakers on improving value for HF care, given its rising prevalence and associated financial burden in the United States; however, little is known about the relationship between payments and mortality for a 30-day episode of HF care. METHODS: Using Medicare claims data for all fee-for-service beneficiaries hospitalized for HF between July 1, 2011, and June 30, 2014, we examined the association between 30-day Medicare payments at the hospital level (beginning with a hospital admission for HF and across multiple settings following discharge) and patient 30-day mortality using mixed-effect logistic regression models...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655825/hypertrophic-cardiomyopathy-clinical-update
#6
REVIEW
Jeffrey B Geske, Steve R Ommen, Bernard J Gersh
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, manifesting as left ventricular hypertrophy in the absence of a secondary cause. The genetic underpinnings of HCM arise largely from mutations of sarcomeric proteins; however, the specific underlying mutation often remains undetermined. Patient presentation is phenotypically diverse, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular outflow obstruction in most patients...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655824/traveling-the-interstices-of-data-sharing
#7
REVIEW
Paul W Armstrong, Robert J Mentz, Cynthia M Westerhout
No abstract text is available yet for this article.
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655823/heart-failure-costs-minority-populations-and-outcomes-targeting-health-status-not-utilization-to-bend-the-cost-effectiveness-curve
#8
EDITORIAL
Marvin A Konstam
No abstract text is available yet for this article.
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655822/clinical-spectrum-and-management-of-heart-failure-in-hypertrophic-cardiomyopathy
#9
REVIEW
Barry J Maron, Ethan J Rowin, James E Udelson, Martin S Maron
Heart failure (HF), characterized by excessive exertional dyspnea, is a common complication within the broad clinical spectrum of hypertrophic cardiomyopathy (HCM). HF has become an increasingly prominent management issue with the reduction in sudden deaths due to use of implantable defibrillators in this disease. Exertional dyspnea ranges in severity from mild to severe (New York Heart Association functional classes II to IV) and not uncommonly becomes refractory to medical management, leading to progressive disability, but largely in the absence of pulmonary congestion and volume overload requiring hospitalization...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655821/opening-opportunities-with-open-data
#10
REVIEW
Alexander R Zheutlin, James Brian Byrd
No abstract text is available yet for this article.
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525328/is-time-of-the-essence-the-impact-of-time-of-hospital-presentation-in-acute-heart-failure-insights-from-ascend-hf-trial
#11
Lukasz P Cerbin, Andrew P Ambrosy, Stephen J Greene, Paul W Armstrong, Javed Butler, Adrian Coles, Adam D DeVore, Justin A Ezekowitz, Adrian F Hernandez, Marco Metra, Randall C Starling, Wilson Tang, John R Teerlink, Adriaan A Voors, Angie Wu, Christopher M O'Connor, Robert J Mentz
OBJECTIVES: As the largest acute heart failure (AHF) trial conducted to date, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial database presented an opportunity to systematically describe the relationship among time of hospital presentation, clinical profile, inpatient management, and outcomes among patients admitted with AHF. BACKGROUND: Time of hospital presentation has been shown to impact outcomes among patients hospitalized with many conditions...
March 7, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525327/obesity-related-heart-failure-with-a-preserved-ejection-fraction-the-mechanistic-rationale-for-combining-inhibitors-of-aldosterone-neprilysin-and-sodium-glucose-cotransporter-2
#12
REVIEW
Milton Packer, Dalane W Kitzman
Obesity-related heart failure with a preserved ejection fraction (HFpEF) is an important phenotype prevalent in the community, especially in people with metabolic disorders (e.g., dyslipidemia, diabetes). These individuals exhibit a marked expansion of plasma volume, but ventricular distensibility is limited, most likely as a result of cardiac microvascular rarefaction acting in concert with myocardial and pericardial fibrosis. Consequently, the increase in plasma volume causes a disproportionate increase in cardiac filling pressures, leading to heart failure, even though systolic ejection is not impaired...
March 7, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29501808/will-biomarkers-succeed-as-a-surrogate-endpoint-in-heart-failure-trials
#13
EDITORIAL
James L Januzzi
No abstract text is available yet for this article.
March 4, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29501807/natriuretic-peptides-as-biomarkers-of-treatment-response-in-clinical-trials-of-heart-failure
#14
Muthiah Vaduganathan, Brian Claggett, Milton Packer, John J V McMurray, Jean L Rouleau, Michael R Zile, Karl Swedberg, Scott D Solomon
OBJECTIVES: This study sought to determine whether treatment-related changes in natriuretic peptides (NPs) predict longer-term therapeutic effects in clinical trials of heart failure (HF). BACKGROUND: The lack of reliable predictors of efficacy of drugs and devices in HF has presented a major hurdle to the development and evaluation of novel therapies. METHODS: The study conducted a trial-level analysis of 16 phase III chronic HF trials completed between 1987 and 2013 studying 18 therapeutic comparisons in 48,844 patients...
March 4, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29501806/sudden-death-in-heart-failure-with-preserved-ejection-fraction-a-competing-risks-analysis-from-the-topcat-trial
#15
Muthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, Inder S Anand, Nancy K Sweitzer, James C Fang, Eileen O'Meara, Sanjiv J Shah, Sheila M Hegde, Akshay S Desai, Eldrin F Lewis, Jean Rouleau, Bertram Pitt, Marc A Pfeffer, Scott D Solomon
BACKGROUND: Sudden death (SD) may be an important mode of death in heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: To investigate rates and predictors of SD or aborted cardiac arrest (ACA) in HFpEF. METHODS: We studied 1,767 patients with HFpEF (EF≥45%) enrolled in the Americas region of the TOPCAT trial. We identified independent predictors of composite SD/ACA with step-wise backward selection using competing risks regression analysis accounting for non-sudden causes of death...
March 4, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525334/comorbidities-and-cardiometabolic-disease-relationship-with-longitudinal-changes-in-diastolic-function
#16
Matthew Nayor, Danielle M Enserro, Vanessa Xanthakis, Martin G Larson, Emelia J Benjamin, Jayashri Aragam, Gary F Mitchell, Ramachandran S Vasan
OBJECTIVES: This study sought to evaluate the course, correlates, and prognosis of longitudinal changes in left ventricular (LV) diastolic dysfunction (DD) in the community-based Framingham Heart Study. BACKGROUND: Relationships of clinical risk factors to longitudinal progression of DD are incompletely understood. METHODS: Diastolic function was assessed by echocardiography performed at consecutive examinations (visits 1 and 2, mean interval 5...
March 1, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525333/innovation-in-heart-failure-treatment-life-expectancy-disability-and-health-disparities
#17
Karen E Van Nuys, Zhiwen Xie, Bryan Tysinger, Mark A Hlatky, Dana P Goldman
OBJECTIVES: The goal of this study was to illustrate the potential benefit of effective congestive heart failure (CHF) treatment in terms of improved health, greater social value, and reduced health disparities between black and white subpopulations. BACKGROUND: CHF affects 5.7 million Americans, costing $32 billion annually in treatment expenditures and lost productivity. CHF also contributes to health disparities between black and white Americans: black subjects develop CHF at a younger age and are more likely to be hospitalized and die of this disease...
March 1, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525332/worsening-heart-failure-during-the-use-of-dpp-4-inhibitors-pathophysiological-mechanisms-clinical-risks-and-potential-influence-of-concomitant-antidiabetic-medications
#18
REVIEW
Milton Packer
Although dipeptidyl peptidase (DPP)-4 inhibitors have been reported to have a neutral effect on thromboembolic vaso-occlusive events in large-scale trials, they act to potentiate several endogenous peptides that can exert deleterious cardiovascular effects. Experimentally, DPP-4 inhibitors may augment the ability of glucagon-like peptide-1 to stimulate cyclic adenosine monophosphate in cardiomyocytes, and potentiation of the effects of stromal cell-derived factor-1 by DPP-4 inhibitors may aggravate cardiac fibrosis...
March 1, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525330/post-exercise-oxygen-uptake-recovery-delay-a-novel-index-of-impaired-cardiac-reserve-capacity-in-heart-failure
#19
Cole S Bailey, Luke T Wooster, Mary Buswell, Sarvagna Patel, Paul P Pappagianopoulos, Kristian Bakken, Casey White, Melissa Tanguay, Jasmine B Blodgett, Aaron L Baggish, Rajeev Malhotra, Gregory D Lewis
OBJECTIVES: This study sought to characterize the functional and prognostic significance of oxygen uptake (VO2 ) kinetics following peak exercise in individuals with heart failure (HF). BACKGROUND: It is unknown to what extent patterns of VO2 recovery following exercise reflect circulatory response during exercise in HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF). METHODS: We investigated patients (30 HFpEF, 20 HFrEF, and 22 control subjects) who underwent cardiopulmonary exercise testing with invasive hemodynamic monitoring and a second distinct HF cohort (n = 106) who underwent noninvasive cardiopulmonary exercise testing with assessment of long-term outcomes...
March 1, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29525329/diastole-tracks-cardiometabolic-risk
#20
EDITORIAL
Walter J Paulus, Elisa Dal Canto
No abstract text is available yet for this article.
March 1, 2018: JACC. Heart Failure
journal
journal
47572
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"